In this protocol, we describe a method to visualize and map dural lymphatic vessels in-vivo using magnetic resonance imaging (MRI) and ex-vivo using histopathological techniques. While MRI protocols for routine imaging of meningeal lymphatics include contrast-enhanced T2-FLAIR and T1-weighted black-blood imaging, a more specific 3D mapping of the lymphatic system can be obtained by administering two distinct gadolinium-based MRI contrast agents on different days (gadofosveset and gadobutrol) and subsequently processing images acquired before and after administration of each type of contrast. In addition, we introduce methods for optimal immunostaining of lymphatic and blood vessel markers in human dura mater ex-vivo.
Background
Among the causes of immune privilege in the brain is the absence of parenchymal lymphatic vessels. However, recent studies have uncovered an extensive lymphatic circulating system in the dura mater of rodents (Aspelund et al., 2015; Louveau et al., 2015) , providing possible routes for the elimination of the brain's waste products and for immune cells to access the deep cervical lymph nodes. In this protocol, we describe a way to: (1) visualize the lymphatic vessels in-vivo in the dura mater using MRI of the head, and (2) assess the local presence of lymphatic vessels using optimized immunostaining methods (Absinta et al., 2017) . In-vivo imaging of lymphatics may enable more detailed studies of mechanisms of waste removal and immune function and their potential abnormalities in various diseases and aging.
Materials and Reagents

1.
Superfrost Plus Microslides (Daigger Scientific, catalog number: EF15978Z) This article is distributed under the terms of the Creative Commons Attribution License (CC BY 4.0).
27.
ImmPRESS™-AP Anti-Mouse IgG (Vector Laboratories, catalog number: MP-5402)
28.
Goat 
Procedure
A. Ethical approval
All human research was carried out under an Institutional Review Board approved protocol, after obtaining informed consent. Formalin-fixed human dura was retrieved at autopsy after obtaining appropriate consent.
B. Human imaging
1.
Place an intravenous line using an 18-22 gauge catheter and pressure infusion tubing linked to an MRI compatible automatic pressure injector. (Figure 1) 
2.
Set up the subject in the MRI scanner with a 32-channel head coil.
3.
Perform cranial MRI as following sequences, a quoted method from Absinta et al. (2017 
e.
Whole-brain T1-SPACE (axial 3D acquisition, acquisition matrix 256 × 256, isotropic resolution 0.9 mm, 112 sections, TR/TE = 600/20 msec, flip angle 120°, echo-train length 28, acquisition time 10 min).
4.
Inject MRI contrast agent, either gadobutrol (0.1 mmol/kg body weight, i.v., Bayer HealthCare) or another standard agent, at a rate of 0.3 ml/min followed by 10 ml of saline flush.
5.
Repeat MRI sequences A3a, A3c, and A3d after completion of the infusion.
6.
Covert scanner-generated DICOM images into NIFTI files for processing using dcm2nii script (nitrc.org, open source).
7.
Co-register pre-and post-contrast images, perform skull-stripping, and subtract pre-contrast images from post-contrast images using standard algorithms implemented in MIPAV software (select Algorithms/Registration/Optimized Automatic Registration and Utilities/Image Calculator/Subtract, respectively).
8.
Import subtraction images into OsiriX software for maximum intensity projection (MIP) 3D rendering (select 2D/3D and then 3D Surface Rendering). (Figure 2) 
9.
For more specific lymphatic imaging, perform Steps B1-B8 using gadofosveset (0.03 mmol/kg body weight, i.v., Lantheus Medical Imaging) rather than gadobutrol. Compare the subtraction images obtained from gadofovest and gadobutrol experiments to identify the lymphatic vessels ( Figure 3 ).
C. Immunohistochemistry, single staining
1.
Fix freshly dissected human dura mater with 10% formalin for 24-48 h at room temperature. Commercial 10% neutral buffered formalin (NBF) contains a small percentage of methanol as a stabilizer, which is not a problem for the majority of procedures. Dura should be fixed as soon as possible using gentle agitation (swirling) of the specimen to aid penetration and fixation reaction. Tissue should be fixed for 24-48 h in NBF, and then stored in 1× PBS with a few drops of 10% formalin at room temperature.
2.
Trim the dura into coronal sections and embed the tissue in a paraffin block (see Figure 4 ). Our recommendation is to focus on the coronal sections near the superior sagittal sinus, which can be easily identified in the dura.
3.
Using rotary microtome, cut the paraffin-embedded tissue block into sections of 3-8 μm thickness. Float the sections in 20% ethanol at room temperature, then transfer them to a 44 °C water bath. (see Note 1 and Video 1)
4.
Transfer the sections onto Superfrost Plus Microslides, as uncoated or uncharged slides may not retain the tissue. Before drying out the slides, remove residual water using a snap of the wrist (imagine wielding a whip), which is important to prevent sections from lifting from slides. Allow the slides to dry vertically overnight, at room temperature, to allow trapped water to escape downward.
5.
Deparaffinize slides using xylene (3 changes of xylene, each 3 min).
6.
Rehydrate slides using 100% alcohol (3 changes, each 3 min), 80% alcohol (3 min) and 50% alcohols (3 min), respectively.
7.
Rinse slides in deionized water for 1 min.
8.
Perform heat-induced antigen retrieval to unmask the antigenic epitope using a steamer. Add tap water to the water base, to the "Max" line, and put the steaming plate onto the water reservoir. Fill a plastic Coplin jar with Target Retrieval Solution or Target Retrieval Solution, at pH 9, and dip deparaffinized/rehydrated slides in the jar. Place the plastic Coplin jar in the steamer and cover it. Turn on the steamer and set the timer for 20 min to incubate it at 95-100 °C. We recommend steamer for heat-induced antigen retrieval instead of microwave or pressure cooker, because it reduces the chance of the section falling off the slide.
9.
Take out the Coplin jar and allow it to cool down for 10 min at room temperature.
10.
Rinse slides gently in Tris-buffed saline (TBS) for 5 min. Use TBS or TBS-0.5% Tween 20 (TBST) during slide washing to prevent sections from falling off.
11.
Immerse sections in 0.3% H2O2 solution in deionized water at room temperature for 10 min to block endogenous peroxidase activity.
12.
Rinse slides gently in TBST for 1 min.
13.
Draw the hydrophobic barrier around the tissues using PAP pen.
14.
Rinse slides gently in TBST 20 for 1 min.
15.
Drop 3-4 of Dako Protein Block on the tissue and incubate at room temperature for 20 min in a humidified chamber.
16.
Gently drop off the excess Dako Protein Block from the slides. Do not rinse the slides in this step.
17.
Apply primary antibody + Dako Antibody Diluent (see Table 1 for antibody dilution factor; 100-200 μl is required to cover the tissue) on the tissues, and incubate at room temperature for 2 h or at 4 °C overnight in a humidified chamber. Make sure that the antibody is spread well on the tissues.
18.
Wash slides in TBST 3 times, 5 min each, using a rocker.
19.
Apply secondary antibody (HRP anti-Mouse IgG or HRP anti-rabbit IgG) on the tissues and incubate for 30 min at room temperature in a humidified chamber.
20.
21.
Drip 3-4 drops of freshly made DAB substrate solution on the slide and check the brown color of antibody signal by microscopy.
22.
If the staining reveals adequate intensity, stop the DAB reaction by dipping slides in deionized water. Over-staining will lead to high background that will obscure the true signals.
23.
Dip slides in Leica Hematoxylin 560 MX for 10 sec, for better morphology and contrast.
24.
Rinse slides in tap water for 5 min.
25.
Immerse slides in bluing solution (Leica Blue buffer or 0.2% ammonia solution or 0.1% lithium carbonate solution).
26.
Dehydrate slides through air dry and coverslip using Permount mounting solution. The mounted slides can be kept at room temperature constantly.
D.
Immunohistochemistry, double staining of D2-40 and CD31 (simultaneous double staining of lymphatic and blood vessels, respectively)
1.
Follow Steps C5-C16 above.
2.
Apply cocktails of primary antibodies + Dako Antibody Diluent on the tissues and incubate at room temperature for 2 h in a humidified chamber.
3.
4.
Apply secondary antibody (HRP anti-Mouse IgG for D2-40 and ImmPRESS™-AP anti-Rabbit IgG for CD31) on the tissues and incubate for 30 min at room temperature in a humidified chamber.
5.
6.
Drip 3-4 drops of freshly made DAB substrate solution on the slide and check the brown color of D2-40 antibody signal by microscopy.
7.
Wash slides in deionized water to stop the DAB reaction.
8.
Drip 3-4 drops of fresh Vector Blue substrate solution on the same slide and check the blue color of CD-31 antibody signal by microscopy.
9.
If the staining reveals enough intensity, stop the Vector Blue reaction by dipping slides in deionized water.
CAUTION: Do NOT perform hematoxylin counterstaining following use of the Vector Blue chromogen.
10.
Dehydrate slides through air dry and coverslip using Permount mounting solution.
E. Immunohistochemistry, double staining of PROX1 and CD31 (sequential double staining)
1.
Follow Steps C5-C22 above. Finish PROX1 immunostaining without counterstaining.
2.
Drip 3-4 drops of Dako Protein Block on the tissue and incubate at room temperature for 20 min in a humidified chamber.
3.
4.
Apply CD31 antibodies + Dako Antibody Diluent on the tissues and incubate at room temperature for 2 h in a humidified chamber.
5.
6.
Apply secondary antibody (ImmPRESS™-AP anti-Rabbit IgG for CD31) on the tissues and incubate for 30 min at room temperature in a humidified chamber.
7.
8.
Drip 3-4 drops of fresh Vector Blue substrate solution on the same slides and check the blue color of CD-31 antibody signal by microscopy.
9.
Stop the Vector Blue reaction by dipping slides in deionized water if the staining reveals enough intensity.
10.
Dehydrate slides through air drying and coverslip using Permount mounting solution.
F. Immunofluorescence, double staining of D2-40 + CD31 (simultaneous double staining)
1.
Follow Steps D1-D3 above.
2.
Apply cocktails of secondary antibodies (Goat anti-Mouse IgG Alexa Fluor 488 and Goat anti-rabbit IgG Fluor 594, 1:200 diluted in Dako Antibody Diluent) on the tissues and incubate for 30 min at room temperature in a humidified chamber.
3.
4.
Dehydrate slides through air dry and coverslip using Fluoro-Gel II Mounting Medium.
5.
Observe the localization of D2-40 and CD31 with fluorescence microscopy.
Data analysis
Scan the entire slide and stitch it together by greater than 10× magnification using Zeiss Microscope, camera, and Zeiss Zen Blue software. On slides double-stained for lymphatic and vascular endothelial markers (D2-40/CD31 and PROX1/CD31), identify lymphatic structures and mark them on the screen under the microscope using the following criteria: On post-gadobutrol coronal T2-FLAIR, the dura does not enhance, and lymphatic vessels (red arrows), running alongside the venous dural sinuses and within the falx cerebri, can be appreciated. 3D rendering, using OsiriX software, of putative dural lymphatics (black) in a 47-year old woman, derived from whole-brain T1-weighted SPACE MRI. (Modified from Figure 1 and Figure S1 in Absinta et al. [2017] . Creative Commons Attribution License) Coronal T1-weighted black-blood images were acquired after intravenous injection of two different gadolinium-based contrast agents during two MRI sessions separated by one week. Dural lymphatics (red arrows in magnified view boxes) were better discerned using gadobutrol (standard MRI contrast agent, which readily enters the dura) compared to gadofosveset (serum albumin-binding contrast agent, which remains largely intravascular) and were localized around dural sinuses, middle meningeal artery, and cribriform plate (white arrows). Notably, the choroid plexus (white arrows) enhanced less with gadofosveset than gadobutrol, whereas meningeal and parenchymal blood vessels (both veins and arteries) did not enhance with any contrast agent and appeared black. (Originally published in Absinta et al. [2017] . Creative Commons Attribution License) A, B and C. Within the dura mater, lymphatic and blood vessels can be differentiated using double staining for PROX1 (a transcription factor involved in lymphangiogenesis, nuclear staining) and CD31 (a vascular endothelial cell marker). E, F and G. Similarly, lymphatic and blood vessels can be differentiated using double staining for D2-40 (endothelial membrane staining) and CD31. 
